Cancer Care in Europe: The European Commission approved perioperative and adjuvant pembrolizumab (Keytruda) plus enfortumab vedotin (Padcev) for adults with resectable muscle-invasive bladder cancer who can’t receive cisplatin, with results from the KEYNOTE-905/EV-303 trial showing a 60% lower risk of event-free survival events versus surgery alone; the approval also covers subcutaneous Keytruda and applies across EU plus Iceland, Liechtenstein, and Norway. Breast Cancer Option: Trodelvy (sacituzumab govitecan) won first-line approval in the EU for metastatic triple-negative breast cancer patients who are not candidates for PD-1/PD-L1 inhibitor therapy, positioning it as a new early treatment choice for a hard-to-treat group. Health Policy & Access: Liechtenstein’s Crown Prince Alois says he would veto a popular initiative to decriminalize early-pregnancy abortion, arguing time limits don’t sufficiently protect life and favoring a medical-indications, criminal-law framework. Patient Travel Rules: UK PIP claimants are being warned that summer trips abroad can affect payments—notify the DWP if travel will be longer than four weeks, with continued eligibility typically up to 13 weeks (or longer for medical treatment). EU Consumer Safety Law: The revised EU Product Liability Directive is moving toward a December 2026 national-law deadline, with early drafts suggesting different interpretations and potentially higher litigation exposure for digital and software-related products.